By Amanda Gardner
EmpowHer's HealthDay Reporter
SUNDAY, June 1 (HealthDay News) -- Colon cancer patients who have the normal version of a particular gene are more likely to benefit from a combination treatment that includes adding the targeted therapy Erbitux to chemotherapy.
Some two-thirds of colon cancer patients have the normal, or "wild-type" form of the gene, according to the new study.
